Proposal of a Selective Prophylaxis Strategy Based on Risk Factors to Prevent Early and Late Pneumocystis jirovecii Pneumonia after Renal Transplantation

다국어 초록 (Multilingual Abstract)

Background: Currently, trimethoprim-sulfamethoxazole is used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, but it is associated with frequent adverse effects. This study evaluated the efficacy and safety of the current protocol and proposes an individualized risk-based prophylaxis protocol.
Methods: The PJP incidence and risk factors during the first 6 months (early PJP) and afterwards (late PJP) was assessed in renal transplant recipients with (prophylaxis group) and without (no-prophylaxis group) 6-month PJP prophylaxis.
Results: In 578 patients, there were 39 cases of PJP during a median follow-up of 51 months. Renal adverse events were encountered frequently during trimethoprim-sulfamethoxazole prophylaxis, leading to premature discontinuation. Patients without the prophylaxis had a significantly higher incidence of early PJP (n=27, 6.6%) compared to patients with the prophylaxis (n=0). The incidence of late PJP was 2.2%, without between-group differences. The factors associated with early PJP were preoperative desensitization and acute rejection within 1 month, whereas late PJP was associated with age, deceased donor transplant, and acute rejection requiring antithymocyte globulin treatment.
Conclusions: Based on the simulation results of several risk-based scenarios, the authors recommend universal prophylaxis up to 6 months post-transplant and extended selective prophylaxis in patients aged ≥57 years and those with a transplant from deceased donors.

참고문헌 (Reference)

1 Delanaye P, "Trimethoprim, creatinine and creatininebased equations" 119 : c187-c193, 2011

2 Urbancic KF, "Taking the challenge: a protocolized approach to optimize Pneumocystis pneumonia prophylaxis in renal transplant recipients" 18 : 462-466, 2018

3 Yiannakis EP, "Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control" 93 : 1-8, 2016

4 Iriart X, "Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis" 15 : 190-199, 2015

5 Faure E, "Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation" 19 : e12735-, 2017

6 de Boer MG, "Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis" 13 : 559-569, 2011

7 Lee SH, "Risk factors for Pneumocystis jirovecii pneumonia (PJP)in kidney transplantation recipients" 7 : 1571-, 2017

8 Stern A, "Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients" 10 : CD005590-, 2014

9 Fishman JA., "Prevention of infection caused by Pneumocystis carinii in transplant recipients" 33 : 1397-1405, 2001

10 Iriart X, "Pneumocystis pneumonia in solid-organ transplant recipients" 1 : 293-331, 2015

11 S. I. Martin, "Pneumocystis pneumonia in solid organ transplantation" Wiley 13 (13): 272-279, 2013

12 Wang EH, "Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past" 14 : 519-525, 2012

13 Thomas CF Jr, "Pneumocystis pneumonia" 350 : 2487-2498, 2004

14 Alexandre K, "Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11cases and review of the literature" 50 : e23-e24, 2018

15 Goto N, "Lifelong prophylaxis with trimethoprim-sulfamethoxazole for prevention of outbreak of Pneumocystis jirovecii pneumonia in kidney transplant recipients" 3 : e151-, 2017

16 Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group, "KDIGO clinical practice guideline for the care of kidney transplant recipients" 9 (9): S1-S155, 2009

17 Schurmann M, "Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients" 28 : 159-163, 2013

18 EBPG Expert Group on Renal Transplantation, "European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia" 17 (17): 36-39, 2002

19 Haynes L, "Effects of aging on T cell function" 21 : 414-417, 2009

20 Mitsides N, "Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients" 19 : 157-163, 2014

21 Opata MM, "B lymphocytes are required during the early priming of CD4+ T cells for clearance of pneumocystis infection in mice" 195 : 611-620, 2015

22 Fraser TN, "Acute kidney injury associated with trimethoprim/sulfamethoxazole" 67 : 1271-1277, 2012